Sign In
Buy GOVX
$1.32
-0.0200 (-1.49%)
At Close: Jun 22, 2026
GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript
11:33pm, Tuesday, 12'th Nov 2024
GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
04:00pm, Tuesday, 12'th Nov 2024
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
09:00am, Tuesday, 05'th Nov 2024
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancer
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
09:00am, Wednesday, 02'nd Oct 2024
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its
GeoVax to Participate in Upcoming Investor Conferences in September
09:00am, Tuesday, 03'rd Sep 2024
ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announc
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
08:59pm, Wednesday, 28'th Aug 2024
ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,
Should You Buy GeoVax Labs Inc. (GOVX) After Golden Cross?
10:55am, Tuesday, 27'th Aug 2024
After reaching an important support level, GeoVax Labs Inc. (GOVX) could be a good stock pick from a technical perspective. GOVX recently experienced a "golden cross" event, which saw its 50-day simpl
GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?
09:29am, Tuesday, 20'th Aug 2024
GeoVax Labs NASDAQ: GOVX is currently a micro-cap biotech stock that multiple Wall Street analysts see massive potential appreciation in. Working on a treatment for a disease that the World Health Org
GeoVax's stock slides 20% after company raises $8.5 million in stock sale
08:09am, Tuesday, 20'th Aug 2024
GeoVax Labs Inc.'s stock GOVX, +1.27% tumbled 20% in premarket trade Tuesday, after the clinical-stage biotech said it's entered an agreement with an institutional investor for the purchase and sale o
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
07:45am, Tuesday, 20'th Aug 2024
ATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
12:11pm, Monday, 19'th Aug 2024
Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.
GeoVax's stock soars 54% to lead rally in companies developing mpox treatments
07:30am, Monday, 19'th Aug 2024
GeoVax Labs Inc.'s stock soared 54% early Monday to lead a fresh rally among companies developing treatments for mpox, after rival Siga Technologies Inc. said a trial of its antiviral failed to meet i
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
09:00am, Thursday, 15'th Aug 2024
Company to Discuss Recent Mpox Developments as Well as Milestones Related to the BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine
GeoVax Labs, Inc. (GOVX) Q2 2024 Earnings Call Transcript
06:15am, Saturday, 10'th Aug 2024
GeoVax Labs, Inc. (NASDAQ:GOVX ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Max Gadicke - Investor Relations David Dodd - Chairman & Chief Executive Officer Mark R
Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company develop
